Patents Assigned to Shanghai Cancer Institute
-
Publication number: 20220152101Abstract: Disclosed is a tumor treatment method, wherein immune effector cells and Gemcitabine are administered to an individual with tumor, and the immune effector cells express receptors having a tumor-specific antigen. Also disclosed is a tumor treatment kit, wherein the kit comprises 1) immune effector cells expressing receptors that recognize tumor antigens; 2) Gemcitabine; 3) a container for containing the substances of 1) and 2) described above; and 4) drug administration instructions for using the kit to treat a tumor.Type: ApplicationFiled: January 7, 2020Publication date: May 19, 2022Applicants: CARSGEN THERAPEUTICS CO., LTD., SHANGHAI CANCER INSTITUTEInventors: Zonghai LI, Xiuqi WU
-
Publication number: 20210113614Abstract: Provided in the present invention is a method for treating tumor. An immune effector cell and a second treatment agent are applied to individual suffering from tumor, wherein the immune effector cell expresses a receptor for recognizing tumor antigen, and wherein the second treatment agent is a compound of formula I or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: February 2, 2019Publication date: April 22, 2021Applicants: CARSGEN THERAPEUTICS CO., LTD., SHANGHAI CANCER INSTITUTEInventors: Zonghai LI, Xiuqi WU
-
Publication number: 20180327470Abstract: Provided is a chimeric antigen receptor-modified immune effector cell carrying a procedural death ligand 1 (PD-L1) blocking agent. Also provided is a method for secreting and expressing a PD-L1 blocking agent using the immune effector cell as a carrier to improve the anti-tumour effect of the chimeric antigen receptor-modified immune effector cell.Type: ApplicationFiled: October 31, 2016Publication date: November 15, 2018Applicants: CARSGEN THERAPEUTICS CO., LTD., SHANGHAI CANCER INSTITUTEInventors: Zonghai Li, Zeyan Pan, Zhimin Shi, Bo Song, Peng Wang
-
Patent number: 8796421Abstract: The present invention provides an epidermal growth factor receptor variant-de4 EGFR protein. The variant lacks the fourth exon of the epidermal growth factor receptor, and promotes tumor cell invasion/metastasis. The present invention also provides an encoding gene for the variant and a method of producing the variant by means of recombination technology.Type: GrantFiled: October 24, 2011Date of Patent: August 5, 2014Assignee: Shanghai Cancer InstituteInventors: Zonghai Li, Min Zhou, Hai Wang, Bizhi Shi, Shengli Yang, Hongyang Wang, Jianren Gu
-
Patent number: 8703917Abstract: Provided are a novel Epidermal growth factor receptor variant-EGFRvA protein, a polynucleotide encoding the EGFRvA protein and a method of preparing the EGFRvA protein via recombination technology. Also provided is a uses of the polynucleotide encoding the EGFRvA protein. The EGFRvA protein has a function of promoting tumor cell invasion or promoting tumor cell migration.Type: GrantFiled: January 26, 2011Date of Patent: April 22, 2014Assignee: Shanghai Cancer InstituteInventors: Zonghai Li, Hai Wang, Min Zhou, Xiaorong Pan, Jianren Gu, Shengli Yang
-
Patent number: 8623328Abstract: Use of DKK-1 protein or the nucleic acid sequence in preparation of cancer diagnostic agents or kits, method to detect liver cancer with the monoclonal antibody thereof, the kit comprising anti-DKK-1 antibody or protein specific nucleic acid probes, together with a label, and method to detecting specific DKK-1 protein expression are disclosed.Type: GrantFiled: August 9, 2012Date of Patent: January 7, 2014Assignee: Shanghai Cancer InstituteInventors: Wenxin Qin, Haitao Zhang, Yanjun Yu, Haiyan You, Shengli Yang, Jianren Gu, Gang Huang, Shile Sheng, Tao Chen
-
Publication number: 20130236465Abstract: The present invention provides an epidermal growth factor receptor variant-de4 EGFR protein. The variant lacks the fourth exon of the epidermal growth factor receptor, and promotes tumor cell invasion/metastasis. The present invention also provides an encoding gene for the variant and a method of producing the variant by means of recombination technology.Type: ApplicationFiled: October 24, 2011Publication date: September 12, 2013Applicant: SHANGHAI CANCER INSTITUTEInventors: Zonghai Li, Min Zhou, Hai Wang, Bizhi Shi, Shengli Yang, Hongyang Wang, Jianren Gu
-
Patent number: 8506963Abstract: The invention provides specific binding proteins and the uses thereof. Particularly, the present invention provides a monoclonal antibody which can effectively bind to epidermal growth factor receptor variant type III (EGFRvIII) or can partially bind to the epidermal growth factor receptor (EGFR) over-expressed in cells, but not bind to EGFR normally-expressed in cells. Furthermore, the present invention said antibody has obvious therapeutic effect on a tumor cell line expressing the EGFRvIII. The invention also provides a method for preparing said monoclonal antibody and a pharmaceutical composition comprising said monoclonal antibody.Type: GrantFiled: September 22, 2009Date of Patent: August 13, 2013Assignee: Shanghai Cancer InstituteInventors: Zonghai Li, Huamao Wang, Hua Jiang, Bizhi Shi, Jianren Gu, Shengli Yang
-
Publication number: 20130195988Abstract: A vascular embolization gelling agent for sustained release of drugs for treating tumors having a drug and a drug carrier. The drugs are antitumor drugs. The drug carrier includes poloxamer polymer and polyvinylpyrrolidone or gel made of the combination, and may be purified before use. The drug carrier accounts for 5-65% of the gel. The particle size of the gel is in the range of 10 nm-150 ?m. The embolization agent is a liquid gel at normal temperature, to facilitate direct transcatheter injection, and is rapidly solidified to the gel state in body with the increase of the temperature; it is used to encapsulate different drugs on demand, and can achieve dual efficacy of embolization and drug treatment through local sustained release of the drug. The present invention can be used as the embolization agent for endovascular interventional therapy for transcatheter arterial chemoembolization of various benign and malignant tumors.Type: ApplicationFiled: March 8, 2013Publication date: August 1, 2013Applicant: Shanghai Cancer InstituteInventor: Shanghai Cancer Institute
-
Publication number: 20130052134Abstract: This invention belongs to the nanotechnology field, and discloses a nano drug delivery system with polyethyleneglycol-poly(lactic-co-glycolic acid)-poly-L-lysine (PEG-PLGA-PLL) polymer as the skeleton. The carrier can have the function of passive targeting through control of the carrier particle size. The polymer skeleton is modified through introducing side chains and specific targeting groups, so as to adjust and improve the carrier performance, and enable the carrier to have the function of active targeting. Such carrier material also has the functions of transporting active substances, tumor treatment and diagnosis, ultrasonic contrast, reversing or reducing drug resistance and so on.Type: ApplicationFiled: December 28, 2010Publication date: February 28, 2013Applicant: Shanghai Cancer InstituteInventors: Yourong Duan, Peifeng Liu, Ying Sun, Ming Shen, Mingjie Zhu, Yanming Sun, Qi Wang, Zelai He, Liubin Qin, Hui Yu, Xiaoyu Li, Xuelian Qi, Xiaoyan Chen, Qiufen Sun, Bingwu Wang
-
Publication number: 20130039920Abstract: The invention provides specific binding proteins and the uses thereof. Particularly, the present invention provides a monoclonal antibody which can effectively bind to epidermal growth factor receptor variant type III (EGFRvIII) or can partially bind to the epidermal growth factor receptor (EGFR) over-expressed in cells, but not bind to EGFR normally-expressed in cells. Furthermore, the present invention said antibody has obvious therapeutic effect on a tumor cell line expressing the EGFRvIII. The invention also provides a method for preparing said monoclonal antibody and a pharmaceutical composition comprising said monoclonal antibody.Type: ApplicationFiled: September 22, 2009Publication date: February 14, 2013Applicant: SHANGHAI CANCER INSTITUTEInventors: Zonghai Li, Huamao Wang, Hua Jiang, Bizhi Shi, Jianren Gu, Shengli Yang
-
Publication number: 20130034558Abstract: Provided are a novel Epidermal growth factor receptor variant-EGFRvA protein, a polynucleotide encoding the EGFRvA protein and a method of preparing the EGFRvA protein via recombination technology. Also provided is a uses of the polynucleotide encoding the EGFRvA protein. The EGFRvA protein has a function of promoting tumor cell invasion or promoting tumor cell migration.Type: ApplicationFiled: January 26, 2011Publication date: February 7, 2013Applicant: SHANGHAI CANCER INSTITUTEInventors: Zonghai Li, Hai Wang, Min Zhou, Xiaorong Pan, Jianren Gu, Shengli Yang
-
Publication number: 20120329669Abstract: Use of DKK-1 protein or the nucleic acid sequence in preparation of cancer diagnostic agents or kits, method to detect liver cancer with the monoclonal antibody thereof, the kit comprising anti-DKK-1 antibody or protein specific nucleic acid probes, together with a label, and method to detecting specific DKK-1 protein expression are disclosed.Type: ApplicationFiled: August 9, 2012Publication date: December 27, 2012Applicant: SHANGHAI CANCER INSTITUTEInventors: Wenxin QIN, Haitao ZHANG, Yanjun YU, Haiyan YOU, Shengli YANG, Jianren GU, Gang HUANG, Shile SHENG, Tao CHEN
-
Patent number: 8263039Abstract: Use of DKK-1 protein or the nucleic acid sequence in preparation of cancer diagnostic agents or kits, method to detect liver cancer with the monoclonal antibody thereof, the kit comprising anti-DKK-1 antibody or protein specific nucleic acid probes, together with a label, and method to detecting specific DKK-1 protein expression are disclosed.Type: GrantFiled: November 11, 2008Date of Patent: September 11, 2012Assignee: Shanghai Cancer InstituteInventors: Wenxin Qin, Haitao Zhang, Yanjun Yu, Haiyan You, Shengli Yang, Jianren Gu, Gang Huang, Shile Sheng, Tao Chen
-
Publication number: 20100317000Abstract: The present invention provides a method for detecting bladder cancer in a subject, comprising the following steps: (a) providing urine sediment sample from said subject; (b) determining methylation pattern of a given sequence within the promoter CpG islands of one or more genes (known as “gene” infra) in the samples; (c) comparing the methylation pattern from said subject with that from normal subject, wherein the hypermethylation of one or more of genes indicates that said subject is suffering from bladder cancer. The present invention also provides a kit for diagnosing bladder cancer.Type: ApplicationFiled: July 23, 2008Publication date: December 16, 2010Applicant: SHANGHAI CANCER INSTITUTEInventor: Jingde Zhu
-
Patent number: 7205109Abstract: The invention provides a method for diagnosing susceptibility of individual cancer (e.g. liver cancer), comprising the steps of detecting individual HC56 gene, transcript and/or protein, and comparing it with normal HC56 gene, transcript and/or protein. The difference show the possibility of individual cancer is higher than that in the normal population. The invention also provides the corresponding detection kit.Type: GrantFiled: March 21, 2002Date of Patent: April 17, 2007Assignee: Shanghai Cancer InstituteInventors: Dafang Wan, Jianren Gu
-
Patent number: 7112419Abstract: The invention relates to a new kind of human protein associated with hepatoma and the polynucleotide encoding the polypeptide and a process for producing the polypeptide by recombinant methods. The present invention also relates to a method of applying the polypeptide for the diagnosis and treatment of various kinds of disease, such as cancer. Further, present invention relates to the antagonist of the polypeptide and therapeutic use of the same. In addition, the invention relates to the use of the same. In addition, the invention relates to the use of polynucleotide encoding the hepatoma associated human protein.Type: GrantFiled: April 17, 2001Date of Patent: September 26, 2006Assignee: Shanghai Cancer InstituteInventors: Xintai Zhao, Dafang Wan, Jianren Gu
-
Patent number: 7037683Abstract: The present invention relates to a novel human longevity assurance protein, the polynucleotide encoding the polypeptide and a process for producing the polypeptide by recombinant methods. The present invention also relates to a method of applying the polypeptide for the treatment of various kinds of disease, such as cancer. Further, the present invention relates to the antagonist of the polypeptide and therapeutic use of the same. In addition, the present invention includes the use of the polynucleotide encoding the human longevity assurance protein.Type: GrantFiled: March 14, 2003Date of Patent: May 2, 2006Assignee: Shanghai Cancer InstituteInventors: Jianren Gu, Shengli Yang
-
Patent number: 6339139Abstract: The invention relates to a gene transfer system binding to a growth factor receptor, comprising 4-element complex gene transfer system consisting of ligand oligopeptide/polycationic polypeptide/endosome release oligopeptide/exogenous DNA or 3-element complex consisting of ligand oligopeptide/polycationic polypeptide/exogenous DNA. The invention exemplifies E5, GE7, GV1 and GV2 systems and they can be targeted for the introduction of exogenous genes into malignant tumor cells or tumor vascular endotheliocytes. They are also able to highly inhibit the growth of tumor cells in animals while p15, p16 or p21WAF−1 was used as exogenous genes. The system according to the invention is a new introduction system in tumor gene therapy.Type: GrantFiled: August 26, 1998Date of Patent: January 15, 2002Assignee: Shanghai Cancer InstituteInventors: Jianren Gu, Peikun Tian